Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Oct;70(5):279-85.
doi: 10.1016/j.pneumo.2014.03.002. Epub 2014 May 27.

[Afatinib (BIBW 2992)]

[Article in French]
N Prim  1 , M Fore  1 , B Mennecier  2
Affiliations
Review

[Afatinib (BIBW 2992)]

[Article in French]
N Prim et al. Rev Pneumol Clin. 2014 Oct.

Abstract

Afatinib (BIBW 2992) is an irreversible multi-target HER receptor tyrosine kinase inhibitor developed in patients with advanced solid tumours. Several phase I studies were conducted in patients with non-small cell lung cancer (NSCLC), as a single agent or in combination. In further phase II or III studies, patients were selected based on the duration of response to first generation EGFR-TKI in previous line (supposed to have greater chance to have an activating EGFR mutation) or based directly on the EGFR activating mutation status. Here, we report and comment the main results of these studies in lung cancer patients. This drug has been approved by the Food and Drug Administration in June 2013 for the first-line treatment of patients with metastatic NSCLC whose tumours have EGFR mutation. In Europe, it has been approved in September 2013 in the same indication.

Keywords: Afatinib; BIBW 2992; Cancer bronchique; EGFR; Inhibiteur tyrosine kinase; Lung cancer; Tyrosine kinase inhibitor.

PubMed Disclaimer

MeSH terms